Published in Clin Experiment Ophthalmol on August 01, 2004
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol (2011) 1.05
Non-cicatricial upper eyelid ectropion. Br J Ophthalmol (2005) 0.91
A family presenting with multiple endocrine neoplasia type 2B: A case report. J Med Case Rep (2011) 0.90
Multiple endocrine neoplasia 2B: delayed presentation, rapid diagnosis. BMJ Case Rep (2013) 0.80
Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome. Eur J Hum Genet (2012) 0.79
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Bone as a source of FGF23: regulation by phosphate? Bone (2004) 1.63
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61
Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust (2005) 1.61
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol (2010) 1.56
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf) (2013) 1.46
Academic health science centres in Australia: let's get competitive. Med J Aust (2011) 1.43
Medial canthal tendon repair for moderate to severe tendon laxity. Clin Experiment Ophthalmol (2004) 1.38
BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery (2010) 1.36
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Clinical features and management of tumors affecting the lacrimal drainage apparatus. Ophthal Plast Reconstr Surg (2006) 1.29
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol (2007) 1.29
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res (2011) 1.22
Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol (2011) 1.21
Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol (2011) 1.19
Phaeochromocytoma: current concepts. Med J Aust (2005) 1.18
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) (2008) 1.15
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med (2011) 1.14
Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab (2002) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol (2014) 1.11
Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist (2008) 1.09
Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone (2006) 1.09
Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology (2007) 1.07
IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol (2007) 1.07
Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab (2003) 1.06
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab (2013) 1.05
MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer (2014) 1.05
MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer (2013) 1.03
Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr (2003) 1.02
Idiopathic sclerosing orbital inflammation. Arch Ophthalmol (2006) 1.00
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer (2008) 1.00
Regulation of c-Ret in the developing kidney is responsive to Pax2 gene dosage. Hum Mol Genet (2006) 1.00
Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J Clin Endocrinol Metab (2012) 1.00
Genetic basis of phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab (2006) 1.00
Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol (2013) 0.99
Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (2003) 0.98
Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann N Y Acad Sci (2006) 0.97
Orbital and periorbital microcystic adnexal carcinoma. Ophthal Plast Reconstr Surg (2005) 0.96
Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab (2009) 0.96
Surgery versus radioiodine therapy as definitive management for graves' disease: the role of patient preference. Thyroid (2007) 0.94
Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene (2003) 0.94
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab (2008) 0.94
Treatment and outcomes of malignant melanoma of the eyelid: a review of 29 cases in Australia. Ophthalmology (2006) 0.93
Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res (2004) 0.93
Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J Surg (2003) 0.92
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J Clin Endocrinol Metab (2005) 0.92
Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist (2011) 0.92
PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology (2005) 0.92
K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma. Clin Endocrinol (Oxf) (2004) 0.92
The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol (2009) 0.91
Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg (2008) 0.91
Familial pituitary tumor syndromes. Nat Rev Endocrinol (2009) 0.90
A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab (2003) 0.90
Orbital apex syndrome secondary to Pseudallescheria boydii fungal sinusitis in an immunocompetent patient. Clin Experiment Ophthalmol (2004) 0.90
Current management options for recurrent adrenocortical carcinoma. Onco Targets Ther (2013) 0.89
Predictive value of the Delphian and level VI nodes in papillary thyroid cancer. ANZ J Surg (2010) 0.88
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer (2010) 0.88
Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. Thyroid (2006) 0.88
Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2007) 0.88
Late orbital haemorrhage around alloplastic orbital floor implants: a case series and review. Clin Experiment Ophthalmol (2002) 0.87
Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer. Cancer Med (2014) 0.87
Minimally invasive parathyroidectomy using the 'focused' lateral approach. I. Results of the first 100 consecutive cases. ANZ J Surg (2002) 0.87
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. Ann Surg Oncol (2014) 0.85
A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol (2015) 0.83
Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol (2010) 0.82
Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) (2005) 0.82
Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol (2014) 0.82
The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J Clin Endocrinol Metab (2009) 0.82
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.81
Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther (2004) 0.81
Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor. PLoS One (2013) 0.80
A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J Pediatr (2004) 0.80
Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol (2002) 0.80
Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma. J Surg Res (2008) 0.80
Impact of month of birth on the development of autoimmune thyroid disease in the United Kingdom and Europe. J Clin Endocrinol Metab (2014) 0.79
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther (2008) 0.79
Evolution of the "autophagamiR". Autophagy (2011) 0.79
A commonly occurring polymorphism upstream of the estrogen receptor alpha alters transcription and is associated with increased HDL. Atherosclerosis (2008) 0.79
Nodal metastasis microRNA expression correlates with the primary tumour in MTC. ANZ J Surg (2012) 0.78
New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a. ANZ J Surg (2006) 0.78
NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2. Am J Surg Pathol (2017) 0.78
Outcomes of minimally invasive surgery for phaeochromocytoma. ANZ J Surg (2009) 0.77
Nonfunctioning parathyroid cancer presenting as a cervical mass. Thyroid (2008) 0.77
Mucoepidermoid carcinoma of the thyroid: a report of three cases and postulated histogenesis. Thyroid (2012) 0.77
Increase in presentations and procedure rates for hyperparathyroidism in Northern Sydney and New South Wales. Med J Aust (2002) 0.77